Groupes virtuels Groupes virtuels
Optimisé par TakingITGlobal
TakingITGlobal

Accueil Accueil Communauté Groupes virtuels Youth Network on HIV/AIDS in Nigeria, South East Zone Messages   
Selectionnez la langue 

Groupe:
Youth Network on HIV/AIDS in Nigeria, South East Zone
  Ouvrir une session S'inscrire

Renseignements Membre(s) Messages Documents Articles relatifs

Message   Message Retour aux messages

De: Chidi Ezegwu [ Profil ]
Sujet: Drug 'stops HIV's entry to cells'
Envoyé: Feb 28th, 2007 - 16:19:41

  Drug 'stops HIV's entry to cells'
A new HIV drug shows promising results in people for whom other
treatments no longer work, a study suggests.

Pfizer's Maraviroc - which blocks HIV's entry to immune system cells -
is one of a number of drugs being developed for this group of patients.

A study found twice as many people on the drug had undetectable virus
levels compared to people on standard drugs.

A UK expert said the development of Maraviroc, detailed at a US
conference, was promising.

Treatment need

The drug acts as a block to the CCR5 receptor which is the "doorway"
which HIV uses to get into CD4-T-cells.

HIV therapies have, for so long, focused on people needing drugs for
their initial treatment
Michael Carter, National Aids Manual

The 24-week safety study reported to the Conference on Retroviruses
and Opportunistic Infections in Los Angeles looked at 1,000 patients.

All were taking their standard medications, but half were also given
Maraviroc while the rest were given the dummy - or placebo - version.

A quarter of those in the placebo arm of the study were found to have
undetectable viral loads at the end of the study, compared with almost
double that number in the group taking Maraviroc - between 41-48%
depending on the dosage they were given.

Those taking the drug also had a higher CD4 count.

Michael Carter, an HIV expert from the UK's National Aids Manual
(Aidsmap) said the drug was the first in a new class to reach this
stage of research.

He said there was another group of drugs, led by Merck's Raltegravir
which are also targeted at this group of patients, but which stop HIV
integrating into cells.

"HIV therapies have, for so long, focused on people needing drugs for
their initial treatment," said Mr Carter.

"But there is a huge and growing number of people who've failed on
first and second-line therapies, who need other drugs later on."

Story from BBC NEWS:
http://news. bbc.co.uk/ go/pr/fr/ -/2/hi/health/ 6404477.stm


---------------------------------
Get your own web address.
Have a HUGE year through Yahoo! Small Business.



TIG Groupes est un outil de communication gratuit de TakingITGlobal. TakingITGlobal se décharge de toute responsabilité de ces groupes discussions.
[ Conditions de service | Politique de confidentialité | Rapporter un problème ]